Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

372 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study.
Assié JB, Crépin F, Grolleau E, Canellas A, Geier M, Grébert-Manuardi A, Akkache N, Renault A, Hauss PA, Sabatini M, Bonnefoy V, Cortot A, Wislez M, Gauvain C, Chouaïd C, Scherpereel A, Monnet I. Assié JB, et al. Among authors: geier m. Cancers (Basel). 2022 Mar 15;14(6):1498. doi: 10.3390/cancers14061498. Cancers (Basel). 2022. PMID: 35326648 Free PMC article.
Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04).
Vergnenegre A, Geier M, Guisier F, Lamy R, Comet B, Le Garff G, Do P, Janicot H, Morel H, Decroisette C, Andre M, Falchero L, Paleiron N, Monnet I; GFPC Team. Vergnenegre A, et al. Among authors: geier m. Cancer Med. 2020 Jan;9(2):432-439. doi: 10.1002/cam4.2716. Epub 2019 Nov 20. Cancer Med. 2020. PMID: 31747137 Free PMC article.
First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study.
Amrane K, Geier M, Corre R, Léna H, Léveiller G, Gadby F, Lamy R, Bizec JL, Goarant E, Robinet G, Gouva S, Quere G, Abgral R, Schick U, Bernier C, Chouaid C, Descourt R. Amrane K, et al. Among authors: geier m. Cancer Med. 2020 Apr;9(7):2309-2316. doi: 10.1002/cam4.2806. Epub 2020 Feb 5. Cancer Med. 2020. PMID: 32022459 Free PMC article. Clinical Trial.
Duration of nivolumab for pretreated, advanced non-small-cell lung cancer.
Geier M, Descourt R, Corre R, Léveiller G, Lamy R, Goarant É, Bizec JL, Bernier C, Quéré G, Amrane K, Gaye E, Lucia F, Burte E, Chouaid C, Robinet G. Geier M, et al. Cancer Med. 2020 Oct;9(19):6923-6932. doi: 10.1002/cam4.3120. Epub 2020 May 15. Cancer Med. 2020. PMID: 32412157 Free PMC article.
PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 "EPNEC" study.
Arpin D, Charpentier MC, Bernardi M, Monnet I, Boni A, Watkin E, Goubin-Versini I, Lamy R, Gérinière L, Geier M, Forest F, Gervais R, Madrosyk A, Guisier F, Serrand C, Locher C, Decroisette C, Fournel P, Auliac JB, Jeanfaivre T, Letreut J, Doubre H, Francois G, Piton N, Chouaïd C, Damotte D. Arpin D, et al. Among authors: geier m. Ther Adv Med Oncol. 2020 Jul 7;12:1758835920937972. doi: 10.1177/1758835920937972. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32684990 Free PMC article.
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
Baize N, Monnet I, Greillier L, Geier M, Lena H, Janicot H, Vergnenegre A, Crequit J, Lamy R, Auliac JB, Letreut J, Le Caer H, Gervais R, Dansin E, Madroszyk A, Renault PA, Le Garff G, Falchero L, Berard H, Schott R, Saulnier P, Chouaid C; Groupe Français de Pneumo-Cancérologie 01–13 investigators. Baize N, et al. Among authors: geier m. Lancet Oncol. 2020 Sep;21(9):1224-1233. doi: 10.1016/S1470-2045(20)30461-7. Lancet Oncol. 2020. PMID: 32888454 Clinical Trial.
Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02-15 study).
Auliac JB, Monnet I, Bizieux A, Greillier L, Geier M, Falchero L, Le Garff G, Lamy R, Guisier F, Ricordel C, Chouaid C, Vergnenegre A; REFRACT GFPC 02-15 investigators. Auliac JB, et al. Among authors: geier m. Lung Cancer. 2021 Nov;161:122-127. doi: 10.1016/j.lungcan.2021.09.007. Epub 2021 Sep 20. Lung Cancer. 2021. PMID: 34583220 Clinical Trial.
Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study.
Descourt R, Pérol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cadranel J, Cortot AB, Guisier F, Galland L, Do P, Schott R, Dansin É, Arrondeau J, Auliac JB, Geier M, Chouaïd C. Descourt R, et al. Among authors: geier m. Cancers (Basel). 2022 Mar 30;14(7):1751. doi: 10.3390/cancers14071751. Cancers (Basel). 2022. PMID: 35406523 Free PMC article.
Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018.
Bylicki O, Tomasini P, Radj G, Guisier F, Monnet I, Ricordel C, Bigay-Game L, Geier M, Chouaid C, Daniel C, Swalduz A, Toffart AC, Doubre H, Peloni JM, Moreau D, Subtil F, Grellard JM, Castera M, Clarisse B, Martins-Lavinas PH, Decroisette C, Greillier L; GFPC. Bylicki O, et al. Among authors: geier m. Eur J Cancer. 2023 Apr;183:38-48. doi: 10.1016/j.ejca.2023.01.014. Epub 2023 Jan 31. Eur J Cancer. 2023. PMID: 36801605 Free article. Clinical Trial.
Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo).
Vergnenegre A, Monnet I, Ricordel C, Bizieux A, Curcio H, Bernardi M, Corre R, Guisier F, Hominal S, Le Garff G, Bylicki O, Locher C, Geier M, Chouaïd C, Robinet G; GFPC team. Vergnenegre A, et al. Among authors: geier m. Lung Cancer. 2023 Apr;178:191-197. doi: 10.1016/j.lungcan.2023.02.020. Epub 2023 Feb 27. Lung Cancer. 2023. PMID: 36868180 Clinical Trial.
372 results